SCHEDULE: Millennium Management Confirms Capricor Therapeutics Stake

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed a Schedule 13G to confirm their beneficial ownership of Capricor Therapeutics, Inc. common stock.

Summary

• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly filed a Schedule 13G.
• This filing confirms their beneficial ownership of Capricor Therapeutics, Inc. common stock.
• The reporting persons collectively beneficially own 2,943,086 shares, representing 5.1% of the class.
• The filing is made in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934.
• The securities are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers controlled by Millennium Group Management LLC and Mr. Englander.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily confirming existing ownership stakes and filing requirements rather than announcing new strategic developments or significant changes in beneficial ownership.

Positives

• Confirmation of a significant ownership stake (5.1%) by a major investment firm in Capricor Therapeutics.
• The filing indicates a stable, established position rather than a new or aggressive accumulation.

Negatives

• The filing does not disclose any new strategic initiatives or changes in investment strategy.
• No indication of increased or decreased stake, suggesting a static position.

Risks

• The filing itself does not introduce new risks, but the underlying investment in Capricor Therapeutics is subject to the company's own business and market risks.
• Potential for future changes in beneficial ownership, though not indicated in this filing.

Future Outlook

This filing is a confirmation of existing beneficial ownership and does not contain forward-looking statements or guidance regarding Capricor Therapeutics' future performance.

Management Comments

• The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC).
• The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard for institutional investors crossing a 5% ownership threshold. This filing confirms Millennium Management's continued significant, but passive, interest in Capricor Therapeutics, aligning with typical institutional investor disclosures.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's holdings, potentially influencing market perception.
• Management of Capricor Therapeutics: Acknowledges the presence of a substantial passive investor.
• Regulators: Fulfills reporting requirements under the Securities Exchange Act of 1934.

Next Steps

• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander will continue to hold their shares in Capricor Therapeutics, Inc.
• Future filings will be made if there are material changes in beneficial ownership or other reportable events.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Capricor Therapeutics, Millennium Management, Investment Disclosure, Securities Exchange Act